Table VI Association of elevated CEP markers with AMD risk genotype

Odds ratios were determined for elevated levels of both CEP markers relative to median AMD levels (≥33 pmol/ml CEP adducts and ≥1.6 CEP autoantibody titer, n = 916 AMD plasma samples). The statistical significance (p values) of differences in CEP marker concentrations between homozygous risk and non-risk donors was determined by the Fisher exact test. Odds ratios, 95% CI, and p values are based on log-transformed CEP marker concentrations.

AMD riskgenotypeAll AMDAdvanced AMD
nOdds ratio (95% CI)p valuenOdds ratio (95% CI)p value
ARMS2
    GG2781.00 (reference)1411.00 (reference)
    GT3061.39 (0.93, 2.07)0.12091.43 (0.84, 2.44)0.2
    TT1241.99 (1.23, 3.24)0.007972.05 (1.12, 3.76)0.03
HTRA1
    GG2941.00 (reference)1751.00 (reference)
    GA2791.59 (1.05, 2.40)0.042041.62 (0.95, 2.76)0.09
    AA1742.07 (1.32, 3.24)0.0021322.17 (1.24, 3.825)0.01
CFH
    TT1601.00 (reference)961.00 (reference)
    TC3840.78 (0.50, 1.21)0.32610.78 (0.45, 1.401)0.4
    CC2441.14 (0.72, 1.81)0.61691.11 (0.62, 2.01)0.8
C3
    CC3171.00 (reference)1951.00 (reference)
    CG2700.92 (0.63, 1.36)0.51900.92 (0.56, 1.48)0.8
    GG1820.85 (0.55, 1.32)0.71240.91 (0.53, 1.57)0.8